Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-035921
Filing Date
2025-03-10
Accepted
2025-03-10 07:50:27
Documents
82
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K prld-20241231.htm   iXBRL 10-K 2974127
2 EX-10.7 prld-ex10_7.htm EX-10.7 101353
3 EX-19 prld-ex19.htm EX-19 88951
4 EX-23.1 prld-ex23_1.htm EX-23.1 8656
5 EX-31.1 prld-ex31_1.htm EX-31.1 13479
6 EX-31.2 prld-ex31_2.htm EX-31.2 13502
7 EX-32.1 prld-ex32_1.htm EX-32.1 10895
8 EX-32.2 prld-ex32_2.htm EX-32.2 9265
9 GRAPHIC img17667762_0.jpg GRAPHIC 362453
10 GRAPHIC img17667762_1.jpg GRAPHIC 167716
11 GRAPHIC img17667762_2.jpg GRAPHIC 116817
12 GRAPHIC img17667762_3.jpg GRAPHIC 141007
  Complete submission text file 0000950170-25-035921.txt   13434867

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20241231.xsd EX-101.SCH 1419304
85 EXTRACTED XBRL INSTANCE DOCUMENT prld-20241231_htm.xml XML 2024259
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39527 | Film No.: 25722178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)